Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage

Journal of Gene Medicine

Volumn 6, Issue 2, 2004, Pages 166-175

  Cichon, Guenter ^a   Willnow, Thomas ^b   Herwig, Susanne ^a   Uckert, Wolfgang ^a   Löser, Peter ^c   Schmidt, Hartmut H ^d   Benhidjeb, Tahar ^e   Schlag, Peter M ^e   Schnieders, Frank ^f   Niedzielska, Dagmara ^f   Heeren, Joerg ^f  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c DeveloGen AG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Section of Pathology   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cholesterol crystals; Gene therapy; LDL receptor overexpression; Liver

Indexed keywords

CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; ALPHA 1 ANTITRYPSIN; SERPINA1 PROTEIN, HUMAN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; IMMUNOREACTIVITY; IN VIVO STUDY; LIPID STORAGE; LIVER; LIVER CELL; LIVER HISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METABOLISM; PROTEIN TRANSPORT; RABBIT; RECEPTOR GENE; SCID MOUSE; TISSUE SECTION; ANIMAL; BLOOD; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ADENOVIRIDAE;

ALPHA 1-ANTITRYPSIN; ANIMALS; CHOLESTEROL; GENE THERAPY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER; MICE; MICE, SCID; RABBITS; RECEPTORS, LDL;

EID: 4644247930     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.473     Document Type: Article

References (46)

1. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-466.
2. Kwiterovich PO Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 2000; 86: 5L-10L.
3. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987; 76 504-507.
4. Laposata M. Fatty acids. Biochemistry to clinical significance. Am J Clin Pathol 1995; 104: 172-179.
5. Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 1975; 6 307-316.
6. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR Jr, Wilson JM. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991; 254: 1802-1805.
7. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
8. Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996; 271: 6852-6860.
9. Kozarsky KF, McKinley DR, Austin LL, Raper SE, Stratford-Perricaudet LD, Wilson JM. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13 695-13 702.
10. Wilson JM, Grossman M, Raper SE, Baker JR Jr, Newton RS, Thoene JG. Ex vivo gene therapy of familial hypercholesterolemia. Hum Gene Ther 1992; 3: 179-222.
11. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-341.
12. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1: 1148-1154.
13. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
14. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
15. Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A 1982; 79: 6777-6781.
16. Foecking MK, Hofstetter H. Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene 1986; 45: 101-105.
17. Takebe Y, Seiki M, Fujisawa J, et al. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol Cell Biol 1988; 8: 466-472.
18. Kim DW, Harada T, Saito I, Miyamura T. An efficient expression vector for stable expression in human liver cells. Gene 1993; 134: 307-308.
19. Liu JS, Park EA, Gurney AL, Roesler WJ, Hanson RW. Cyclic AMP induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription is mediated by multiple promoter elements. J Biol Chem 1991; 266 19 095-19 102.
20. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-810.
21. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430.
22. Heeren J, Steinwaerder DS, Schnieders F, Cichon G, Strauss M, Beisiegel U. Nonphysiological overexpression of low-density lipoprotein receptors causes pathological intracellular lipid accumulation and the formation of cholesterol and cholesteryl ester crystals in vitro. J Mol Med 1999; 77: 735-743.
23. Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A 1996; 93: 10 285-10 290.
24. Loser P, Sandig V, Kirillova I, Strauss M. Evaluation of HBV promoters for use in hepatic gene therapy. Biol Chem Hoppe Seyler 1996; 377: 187-193.
25. Sandig V, Loser P, Lieber A, Kay MA, Strauss M. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Ther 1996; 3: 1002-1009.
26. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988; 163: 614-617.
27. Cichon G, Boeckh-Herwig S, Elezkurtaj S, Schmidt HH, Hofmann C, Arnold W. Hepatocarcinoma cells constitutively expressing adenoviral E1-genes provide a tumor model for intratumoral replication of E1-deficient adenoviruses. Anticancer Res 2002; 22: 197-201.
28. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
29. Herz J, Qiu SQ, Oesterle A, DeSilva HV, Shafi S, Havel RJ. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc Natl Acad Sci U S A 1995; 92: 4611-4615.
30. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264: 1471-1474.
31. Garver WS, Heidenreich RA. The Niemann-Pick C proteins and trafficking of cholesterol through the late endosomal/lysosomal system. Curr Mol Med 2002; 2: 485-505.
32. Strauss JF, Liu P, Christenson LK, Watari H. Sterols and intracellular vesicular trafficking: lessons from the study of NPC1. Steroids 2002; 67: 947-951.
33. Pagano RE, Puri V, Dominguez M, Marks DL. Membrane traffic in sphingolipid storage diseases. Traffic 2000; 1: 807-815.
34. Du H, Sheriff S, Bezerra J, Leonova T, Grabowski GA. Molecular and enzymatic analyses of lysosomal acid lipase in cholesteryl ester storage disease. Mol Genet Metab 1998; 64: 126-134.
35. Labrune P, Bedossa P, Huguet P, Roset F, Vanier MT, Odievre M. Fatal liver failure in two children with Niemann-Pick disease type B. J Pediatr Gastroenterol Nutr 1991; 13: 104-109.
36. D'Agostino D, Bay L, Gallo G, Chamoles N. Cholesterol ester storage disease: clinical, biochemical, and pathological studies of four new cases. J Pediatr Gastroenterol Nutr 1988; 7: 446-450.
37. Smanik EJ, Tavill AS, Jacobs GH, et al. Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher's diseases: implications for the treatment of inherited metabolic disease. Hepatology 1993; 17: 42-49.
38. Coelho CA, Balarin MA, Coelho KI. Cholesteryl ester storage disease. Report of a case. Arq Gastroenterol 1987; 24: 184-187.
39. Kuriwaki K, Yoshida H. Morphological characteristics of lipid accumulation in liver-constituting cells of acid lipase deficiency rats (Wolman's disease model rats). Pathol Int 1999; 49: 291-297.
40. Kuemmel TA, Thiele J, Schroeder R, Stoffel W. Pathology of visceral organs and bone marrow in an acid sphingomyelinase deficient knock-out mouse line, mimicking human Niemann-Pick disease type A. A light and electron microscopic study. Pathol Res Pract 1997; 193 663-671.
41. Chen SJ, Rader DJ, Tazelaar J, Kawashiri M, Gao G, Wilson JM. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther 2000; 2: 256-261.
42. Oka K, Pastore L, Kim IH, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103: 1274-1281.
43. Smith JR, Osborne TF, Goldstein JL, Brown MS. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem 1990; 265: 2306-2310.
44. Soutar AK, Knight BL. Structure and regulation of the LDL-receptor and its gene. Br Med Bull 1990; 46: 891-916.
45. Sakai J, Rawson RB. The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport. Curr Opin Lipidol 2001; 12: 261-266.
46. Sun XM, Neuwirth C, Wade DP, Knight BL, Soutar AK. A mutation (T-45C) in the promoter region of the low-density-lipoprotein (LDL)-receptor gene is associated with a mild clinical phenotype in a patient with heterozygous familial hypercholesterolaemia (FH). Hum Mol Genet 1995; 4: 2125-2129.